The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
A potential single-injection-cure for Hepatitis C, Benitec’s revolutionary TT-034 will soon be tested in previous non-responders at Duke Clinical Research Institute.
Continue reading »
Riddled with hard personal decisions and ethical quandaries, many people are opting to pass on current Hepatitis C therapy. Instead, they are waiting for the arrival of an interferon-free drug regimen that is still in development.
Continue reading »
Two pharmaceutical companies will work together next quarter on a mid-stage trial for an interferon-free Hepatitis C treatment.
Continue reading »Joint investment for BL-8030 is in advanced negotiation, potentially expediting the development of BiolineRX’s experimental Hepatitis C drug.
Continue reading »By discontinuing development on filibuvir, Pfizer takes a back seat in the race for an improved Hepatitis C drug regimen.
Continue reading »
Gilead’s sofosbuvir is on the cusp of achieving a preliminary stamp of approval as the first interferon-free treatment for Hepatitis C.
Continue reading »A Veterans Affairs task force created a model for coordinating patient care to optimize treatment for Hepatitis C – making the patient’s location virtually irrelevant.
Continue reading »Although still in development, Daclatasvir appears to cause the fastest decline in Hepatitis C viral load seen to date. A combined effort between mathematicians, clinicians and scientists has found that this drug has two, simultaneous modes of action.
Continue reading »Inching closer to finding a successful interferon-free treatment for Hepatitis C, Gilead’s Neutrino and Fission trials posted encouraging results for the drug, sofosbuvir.
Continue reading »Interferon monotherapy is an option for treating certain individuals with Hepatitis C; however, a new review claims that repeating this treatment can be devastating.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
